Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
HyperCharge operates on a direct-care model
The BPC-157 First investigations of the effects on BPC-157 were conducted in the late 1990s by scientific research group in Croatia, and it was studied in various controlled experimental models regarding to response of gastric tissue response and inflammation associated processes
Critical safety considerations for laboratory use include potential immunogenicity concernswith peptide therapeutics commonly showing injection site reactions (20-40% with subcutaneous administration) and possible antidrug antibody formationalong with theoretical concerns that pro-angiogenic properties could potentially influence experimental tumor models, requiring appropriate controls in oncology-related research
Join our community of researchers staying current with peptide science developments.Full NameEmail AddressPrimary Research FocusSubscribe to Research Updates We respect your privacy
systemic adverse events are rare in preliminary reports
ResearchGate preprint
